Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations
Vivek Thakkar, Karen A Patterson, Wendy Stevens, Michelle Wilson, Janet Roddy, Joanne Sahhar, Susanna Proudman, Pravin Hissaria, Mandana Nikpour
CLINICAL RHEUMATOLOGY | SPRINGER LONDON LTD | Published : 2018
Studies suggest elevated serum intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) levels may be markers of pulmonary arterial hypertension in systemic sclerosis (SSc-PAH). We sought to evaluate whether ICAM-1 and VCAM-1 levels are useful screening biomarkers for incident SSc-PAH. In this cross-sectional study, four groups were selected from the Australian Scleroderma Cohort Study: group 1 (n = 15) had definite PAH; group 2 (n = 19) had interstitial lung disease (ILD); group 3 (n = 30) were SSc-controls; and group 4 (n = 34) were healthy controls. Serum ICAM-1 and VCAM-1 levels were measured using the Millipore Milliplex MAP Human 2-Plex Panel. There wer..View full abstract
Related Projects (1)
Awarded by National Health and Medical Research Council (NHMRC) of Australia Career Development Fellowship
Financial support for the present study was provided by Scleroderma Australia, Arthritis Australia, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia and Pfizer. Dr. Nikpour holds a National Health and Medical Research Council (NHMRC) of Australia Career Development Fellowship (APP1126370).